Sun Pharma Q3 FY26 Results: Net Profit Up 16% to ₹3,369 Crore, Declares ₹11/Share Dividend

Mumbai, 31 January 2026 – Sun Pharmaceutical Industries Limited, India's largest pharmaceutical company, announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a 16% year-on-year growth in net profit to ₹3,369 crore for Q3 FY26 and declared an interim dividend of ₹11 per equity share.

Key Financial Highlights (Consolidated) – Q3 FY26

Revenue from Operations: ₹15,469 crore, up 15.1% YoY
EBITDA: ₹4,949 crore, up 23.4% with margin at 31.9%
Net Profit: ₹3,369 crore, up 16.0% YoY
Earnings Per Share (EPS): ₹14.0 (not annualized)
Interim Dividend: ₹11.00 per share (Record Date: 5th February 2026)
R&D Investment: ₹893 crore (5.8% of sales)

Segment-Wise Performance (Q3 FY26)

India Formulations: Sales grew 16.2% to ₹4,999 crore, accounting for 32.3% of total sales. Sun Pharma maintains its position as India's No. 1 pharma company with market share increasing to 8.4%.
US Formulations: Sales at $477 million, marginally up 0.6%. Innovative Medicines growth offset generic business decline.
Emerging Markets: Sales grew 21.6% to $337 million.
Rest of World: Sales up 14.5% to $296 million.
Global Innovative Medicines: Sales reached $423 million (including $55 million milestone payment), accounting for 21.2% of sales ex-milestone.

Exceptional Items Impact

The financial results include exceptional items related to:

Discontinuation of development work of SCD-044 (₹2,876 million)
Settlement of litigation in the US (additional charge of ₹1,140 million in Q3)
Impact of new Labour Codes (incremental cost of ₹2,587 million standalone / ₹3,755 million consolidated)

Business Updates

Launched Unloxcyt in the US and introduced Ilumya in India
Launched 12 new products in India during the quarter
Innovative R&D pipeline includes five novel entities in clinical stage
US portfolio includes 550 approved ANDAs with 116 awaiting FDA approval

Management Commentary

Kirti Ganorkar, Managing Director, stated: "Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our Branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India."

Dividend Declaration

The Board declared an interim dividend of ₹11.00 per share for FY26, higher than the ₹10.50 per share dividend declared in the previous year. The record date for eligibility is 5th February 2026.

About Sun Pharmaceutical

Sun Pharma is the world's leading specialty generics company with presence in Innovative Medicines, Generics and Consumer Healthcare. It is the largest pharmaceutical company in India and a leading generic company in the US and Global Emerging Markets.

Scrip Codes: BSE: 524715 | NSE: SUNPHARMA
Next Key Date: Record Date for Interim Dividend - 5th February 2026